Profil
Victor Brantl currently works as a Vice President of Research and Development at Mepha AG.
Postes actifs de Victor Brantl
| Sociétés | Poste | Début |
|---|---|---|
Mepha AG
 Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | Directeur Technique/Scientifique/R&D | 08/02/2010 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | Health Technology |
